Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
